Poland's oncology clinical trials market is projected to grow from $73.4 Mn in 2022 to $116.5 Mn by 2030, registering a CAGR of 5.95% during the forecast period of 2022-30. The market will be driven by the increased prevalence of cancer and a good regulatory framework. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Roche Holding AG, Novartis International AG & Ryvu Therapeutics.
The Poland Oncology Clinical Trials Market is projected to grow from $73.4 Mn in 2022 to $116.5 Mn by 2030, registering a CAGR of 5.95% during the forecast period of 2022 - 2030. Between the first of the year 2021 and the first of the year 2022, 559 clinical studies were launched. The bulk of trials started during this time period were Phase 3 studies (203), with a considerable number of Phase 2 investigations (144). The majority of those trials were carried out in the field of oncology (121). The Polish National Cancer Registry collected data on around 171.2 thousand new cancer cases and 100.3 thousand cancer deaths in 2019. Male malignancies with the highest prevalence were prostate (20.6%), lung (16.1%), colon (6.8%), bladder (6.4%), and rectal (4.2%).
Poland is one of the top nations in Europe for oncology clinical trials. The country possesses an advanced healthcare infrastructure and a skilled workforce, making it an appealing location for clinical research. According to clinicaltrials.gov, there are over 2,000 active clinical studies in Poland as of March 2023, with a considerable proportion of them in cancer. Novartis, Roche, AstraZeneca, Pfizer, Merck, and Bristol-Myers Squibb are among the top pharmaceutical firms engaging in oncology clinical trials in Poland. Also, some local pharmaceutical businesses in Poland, such as Adamed Group, Polpharma, and Celon Pharma, are actively engaging in oncology clinical trials.
Overall, the situation for oncology clinical trials in Poland is strong, with a good regulatory framework, skilled personnel, and a high incidence of cancer in the population, making it an appealing location for clinical research in oncology.
Market Growth Drivers
The increased prevalence of cancer, a good regulatory framework, experienced personnel, and patient access are all driving the rise of oncology clinical trials in Poland. The Polish government has developed measures to stimulate clinical research in the nation, such as simplified clinical trial approval procedures, making it simpler for pharmaceutical firms to perform clinical trials in Poland.
Market Restraints
There are also various constraints that may impede the industry's expansion. One of the key constraints is competition from other nations in Central and Eastern Europe that are also recruiting oncology clinical trials which have the potential to reduce the number of clinical trials undertaken in Poland. Moreover, restricted healthcare financing may limit the resources available for clinical research. Despite the positive regulatory climate, businesses may still encounter regulatory hurdles, such as approval delays or regulatory changes, which may hinder growth. Since English is not commonly spoken in Poland, international organizations conducting clinical trials in the country may face linguistic obstacles.
Key Players
November 2022, A Polish firm Ryvu Therapeutics, is developing innovative medications for the treatment of blood cancer and solid tumors using targeted therapy.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
6. Methodology and Scope
By Phase (Revenue, USD Billion):
By Study Design Outlook (Revenue, USD Billion):
By Indication Outlook (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.